APA (7th ed.) Citation

Zhu, B., Tang, Y., Xue, M., Wu, Y., Zhao, Y., & Fan, W. (2024). Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study. Journal of clinical oncology, 42(16_suppl), e16145. https://doi.org/10.1200/JCO.2024.42.16_suppl.e16145

Chicago Style (17th ed.) Citation

Zhu, Bowen, Yiyang Tang, Miao Xue, Yanqin Wu, Yue Zhao, and Wenzhe Fan. "Transarterial Chemoembolization (TACE) Combined with Donafenib as First-line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): A Real-world Clinical Study." Journal of Clinical Oncology 42, no. 16_suppl (2024): e16145. https://doi.org/10.1200/JCO.2024.42.16_suppl.e16145.

MLA (9th ed.) Citation

Zhu, Bowen, et al. "Transarterial Chemoembolization (TACE) Combined with Donafenib as First-line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): A Real-world Clinical Study." Journal of Clinical Oncology, vol. 42, no. 16_suppl, 2024, p. e16145, https://doi.org/10.1200/JCO.2024.42.16_suppl.e16145.